GDF15 and AL amyloidosis: The result obtained in this cohort of patients show that (1) the novel biomarkers sST2 and GDF-15 show satisfactory prognostic values for overall survival in patients with AL amyloidosis, (2) sST2 and GDF-15 had incremental prognostic values over the conventional biomarkers NT-proBNP and TnT, and (3) sST2 and GDF-15 further discriminated prognosis of patients at advanced revised Mayo stages.